Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -10.11 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 3.33 | 4.48 | 3.00 | 2.53 | 2.15 | 0.90 | 0.96 | 1.44 | 1.21 | 0.73 | 0.84 | 0.54 | 0.46 | 1.19 | 1.03 | 1.75 | 2.74 | 2.18 | 2.42 | 3.10 | 2.07 |
| — | +398.2% | +211.9% | +75.2% | +77.9% | +24.0% | +13.8% | +169.6% | +160.2% | -38.9% | -18.1% | -69.4% | -83.0% | -45.6% | -57.4% | -43.5% | +32.2% | -20.0% | +87.4% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.7% | -9.6% | -8.2% | -7.8% | -8.2% | -8.7% | -7.5% | -5.5% | -5.1% | -4.4% | -4.1% | -4.2% | -5.4% | -6.5% | -6.0% | -5.2% | -5.1% | -4.1% | -3.5% | -2.9% | -2.9% |
| — | -11.0% | -8.7% | -40.6% | -62.2% | -94.8% | -85.7% | -31.1% | +6.5% | +32.1% | +32.7% | +18.9% | -7.0% | -58.6% | -71.0% | -81.4% | -77.7% | -118.6% | -26.8% | — | — | |
| ROA | -29.2% | -9.1% | -7.7% | -7.3% | -7.8% | -8.3% | -7.2% | -5.3% | -4.9% | -4.3% | -3.9% | -4.0% | -5.2% | -6.3% | -5.8% | -5.0% | -4.9% | -4.0% | -3.4% | -2.8% | -2.8% |
| — | -9.2% | -6.7% | -37.5% | -59.3% | -92.8% | -85.2% | -32.3% | +4.9% | +31.4% | +32.6% | +19.4% | -5.4% | -56.0% | -68.1% | -78.2% | -74.4% | -114.9% | -40.2% | +73.5% | — | |
| ROIC | -28.4% | -8.3% | -7.3% | -7.1% | -7.6% | -7.9% | -7.0% | -5.6% | -5.5% | -4.9% | -4.3% | -4.4% | -5.3% | -6.0% | -5.5% | -4.8% | -5.3% | -7.2% | -11.5% | -13.4% | -24.9% |
| — | -6.1% | -4.4% | -26.7% | -37.9% | -60.7% | -62.6% | -28.5% | -3.9% | +19.1% | +21.6% | +9.0% | -0.0% | +15.5% | +52.5% | +64.1% | +78.7% | +76.4% | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | +10.1% | +33.5% | -25.1% | -12.6% | -11.7% | -12.0% | -12.2% | -11.6% | -9.1% | -5.5% | -2.6% | +0.3% | +2.0% | +19.1% | +18.6% | +17.7% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 17.14 | 18.86 | 22.28 | 17.14 | 18.71 | 25.13 | 28.37 | 29.31 | 34.61 | 41.42 | 38.61 | 29.58 | 23.77 | 25.22 | 35.25 | 31.10 | 33.47 | 48.96 | 68.22 | 72.96 | 71.81 |
| — | -24.9% | -21.5% | -41.5% | -45.9% | -39.3% | -26.5% | -0.9% | +45.6% | +64.2% | +9.5% | -4.9% | -29.0% | -48.5% | -48.3% | -57.4% | -53.4% | -58.8% | -38.6% | +369.2% | — | |
| Quick Ratio | 17.14 | 18.86 | 22.28 | 17.14 | 18.71 | 25.13 | 28.37 | 29.31 | 34.61 | 41.42 | 38.61 | 29.58 | 23.77 | 25.22 | 35.25 | 31.10 | 33.47 | 48.96 | 68.22 | 72.96 | 71.81 |
| — | -24.9% | -21.5% | -41.5% | -45.9% | -39.3% | -26.5% | -0.9% | +45.6% | +64.2% | +9.5% | -4.9% | -29.0% | -48.5% | -48.3% | -57.4% | -53.4% | -58.8% | -38.6% | +369.2% | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DSGN stock.
Design Therapeutics, Inc.'s current P/E is -10.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Design Therapeutics, Inc.'s business trajectory between earnings reports.